IncRNA MT1JP-overexpression abolishes the silencing of PTEN by miR-32 in hepatocellular carcinoma

SHUHUA ZHANG1, JIANQUN XU2, QING CHEN1, FAN ZHANG1, HONGJUAN WANG2 and HONGRONG GUO2

1Department of Hepatobiliary Surgery, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei 430022; 2Department of Respiratory Medicine, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China

Received August 4, 2020; Accepted January 27, 2021

DOI: 10.3892/ol.2021.12865

Abstract. Previous studies have shown that long non-coding RNA (lncRNA) MT1JP plays a role as a tumor suppressor in several types of cancer. The present study aimed to explore the role of MT1JP in hepatocellular carcinoma (HCC). Paired HCC and non-tumor tissues from 64 patients with HCC were subjected to RNA isolation and reverse transcription-quantitative PCR (RT-qPCR) to analyze the differential expression of MT1JP, microRNA (miR)-32 and phosphatase and tensin homolog (PTEN) in HCC. Cell transfections, followed by RT-qPCR and western blotting, were carried out to investigate the interactions among MT1JP, miR-32 and PTEN. The role of MT1JP, miR-32 and PTEN in regulating HCC cell proliferation was assessed using a Cell Counting Kit-8 assay. It was found that MT1JP was downregulated in HCC cancer tissues compared with that in non-cancer tissues. Survival analysis showed that patients with low MT1JP expression levels exhibited a significantly higher 5-year overall survival rate compared with patients with high MT1JP levels. The expression of MT1JP in HCC tissues was positively associated with PTEN and negatively associated with miR-32. Overexpression of MT1JP increased the expression levels of PTEN and decreased the expression levels of miR-32. Overexpression of miR-32 did not affect the expression of MT1JP but decreased the expression levels of PTEN and attenuated the effect of overexpression of MT1JP on the expression of PTEN. Overexpression of MT1JP and PTEN decreased the proliferation of HCC cells. Overexpression of miR-32 played an opposite role and attenuated the effects of overexpression of MT1JP. Therefore, MT1JP may upregulate PTEN by downregulating miR-32 to regulate HCC cell proliferation.

Introduction

Hepatocellular carcinoma (HCC) is the most common subtype of liver cancer with a steady increase in incidence and remains the fifth most common cancer worldwide (1). Every year, >780,000 novel HCC cases are reported globally, causing ~745,000 mortalities (2,3). Patients at different stages of HCC have tried different treatment strategies, but the median overall survival of patients is only 6-20 months (3). Therefore, it is urgent to find an effective treatment.

Long non-coding RNAs (IncRNAs, >200 nucleotides in length) are RNA transcripts without protein-coding capacity but with the ability to regulate gene expression and participate in human diseases, including osteoarthritis (4), non-alcoholic fatty liver disease (5) and rheumatoid arthritis (6). IncRNAs play an important role in a variety of physiological and pathological processes such as cell proliferation and apoptosis, cell proliferation and senescence, immune activation and inactivation (7,8). Multiple IncRNAs have been confirmed by previous studies to play a vital role in HCC, such as TMPO-AS1 (9), MYLK-AS1 (10) and DLX6-AS1 (11). However, there are relatively few reports on the role of IncRNA MT1JP in HCC, and its ability to predict the prognosis of this disease is still limited.

MicroRNA (miRNA/miR) is a type of endogenous non-coding single-stranded small RNA, which is widely distributed in eukaryotes. It is composed of 19-25 nucleotides (12). A growing body of research over the past decades has demonstrated that miRNAs can act as tumor suppressors or promoters during the development of HCC (13,14). miR-32 is abnormally expressed in gastric cancer (15), glioma (16) and cervical cancer(17). However, the function and mechanism of miR-32 in HCC needs further exploration.

PTEN is a tumor suppressor gene with critical roles in diverse biological processes, such as cell cycle regulation and apoptosis (18). In cancer biology, PTEN mainly inhibits the PI3K/Akt signaling pathway, which is the main cell survival pathway, to induce cell death and suppress tumor growth (19).

Correspondence to: Dr Shuhua Zhang, Department of Hepatobiliary Surgery, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, 1277 JieFang Avenue, Wuhan, Hubei 430022, P.R. China
E-mail: 451233285@qq.com

Dr Jianqun Xu, Department of Respiratory Medicine, Wuhan Third Hospital, Tongren Hospital of Wuhan University, 216 GuanShan Road, Hongshan, Wuhan, Hubei 430060, P.R. China
E-mail: 375738977@qq.com

Key words: MT1JP, hepatocellular carcinoma, survival, PTEN, miR-32
It is known that PTEN in HCC can be targeted by oncogenic miRNAs, such as miR-32 (20). The current study investigated the expression levels of MT1JP and its prognostic value for patients with HCC, and explored whether the PTEN/miR-32 axis was involved in HCC progression via interaction with lncRNA MT1JP. The present study may identify a novel therapeutic target for HCC.

Materials and methods

Study patients. This study included 64 patients with HCC (36 males, 28 females; age range, 33-67 years old; mean age, 51.8±6.0 years old) selected from the 136 patients with HCC admitted to the Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology (Wuhan, China) between April 2010 and April 2014. All patients were treated with surgical resection of the primary tumors and/or targeted therapies, radiotherapies and chemo-therapies according to their conditions. The study was approved by the review board of the Ethics Committee of the aforementioned hospital. Inclusion criteria included: i) patients had not received radiofrequency ablation preoperatively; ii) newly diagnosed HCC case and iii) completed treatment and a 5-year follow-up in Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology. Exclusion criteria included: i) Recurrent patients with HCC, ii) previous history of cancer, iii) family history of cancer and iv) other clinical disorders. All 64 patients with HCC provided written informed consent.

Tissue samples, treatment and follow-up. Before initiation of therapies, liver biopsy was performed under the guidance of MRI to collect both HCC and non-tumor (within 3 cm of the tumor) tissues. All tissues were snap-frozen and then transferred into a -80°C freezer before use. HCC tissue samples were sectioned at 5-µm. The clinicopathological features of the patient specimens and the histological diagnosis of all HCC and normal tissues were independently reviewed and approved by two experienced pathologists. Pathologists performed a blinded assessment of the specimens. The TNM stage was evaluated based on the American Cancer Joint Commission Cancer Staging Manual (21). From the day of admission, all patients were followed-up for 5 years in a monthly manner through telephone to record their survival. The overall survival was defined as the day of diagnosis to the day of death or last follow-up. Patients who died of other causes or were lost during the follow-up were excluded. The 5-year overall survival rate was calculated as the proportion of the survivors among all patients with HCC at 5 years after hepatectomy.

HCC cells and transfections. Human HCC cell line SNU-398 (American Type Culture Collection) was used. A mixture of 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) and 90% RPMI 1640 medium was used to cultivate cells. Cells were cultivated under the conditions of 37°C, 95% humidity and 5% CO₂. Cells were harvested at the confluence of 70-80% to perform cell transfections. The overexpression pcDNA3.1-MT1JP (MT1JP), pcDNA3.1-PTEN (PTEN) and control pcDNA3.1 recombinant plasmids were constructed by Shanghai GenePharma Co., Ltd. miRNA-NC and miR-32 mimic were obtained from Guangzhou RiboBio Co., Ltd. Lipofectamine 2000® (Sangon Biotech Co., Ltd.) was used to transfect 35 nM miRNA (miRNA-NC or miR-32) or 2 µg plasmid for 24 h in six-well plates. The control (C) cells for all transfections were untransfected cells. At 24 h post-transfection at the room temperature, cells were harvested to perform subsequent experiments. The sequences were as follows: miR-32 Mimic, 5'-AGUAUAGCUCCUGACUG AGCU-3' and miRNA-NC, 5'-UGCUCCGGACGUGUG AGGGU-3'.

Reverse transcription-quantitative (RT-qPCR). Total RNA from tissues and cells was extracted using TRIZol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) following the manufacturer's protocol. Total RNA was reverse transcribed into cDNA using oligo (dT)15, random primers (GenScript), M-MLV reverse transcriptase, dNTPs, 5X buffer and RNase inhibitor (all Tiangen Biotech Co., Ltd.) at 25°C for 10 min, 42°C for 50 min and 80°C for 10 min. QuantiTect SYBR® Green PCR kit (Qiagen, Inc.) was used to prepare qPCR mixtures for measuring the expression levels of MT1JP and PTEN. GAPDH was used as the endogenous control of MT1JP and PTEN. To measure the expression levels of miR-32, all steps were performed using All-in-One™ miRNA qRT-PCR Detection kit (GeneCopoeia, Inc.). U6 was used as the endogenous control of miR-32. The following thermocycling conditions were used for the qPCR: Initial denaturation at 94°C for 5 min; followed by 40 cycles at 94°C for 10 sec, 60°C for 20 sec and 72°C for 30 sec; and final extension at 72°C for 150 sec. The following primer pairs were used for the qPCR: MT1JP forward: 5'-GCAAAGGAGACGTCGGAGA-3' and reverse: 5'-TCCAGGTTTGCAGTTGT-3'; PTEN forward: 5'-TGGGTT CGACTTAG-3' and reverse: 5'-GGGGTTGTATGGTTTCTTTA AAAG-3'; miR-32 forward: 5'-GCCGCCGTATTTGACA TTACT-3' and reverse: 5'-TCGGTATCCAGTGAGGGTC-3'; GAPDH forward: 5'-AGATCATCACGAAATGCTCTC-3' and reverse: 5'-TAAGTTCCTTCCAGGATACAA-3' and U6 forward: 5'-CTCGGTTCGCGAGCACA-3' and reverse: 5'-AAGCGTTCGAAATGGCT-3'. The 2^-ΔΔCq method (22) was used for data analysis and all experiments were performed in three replicates.

Western blotting. SNU-398 cells were counted, and total proteins in 3×10⁵ cells were extracted using RIPA solution (Sangon Biotech Co., Ltd.). Protein samples were incubated in boiling water for 10 min to denature proteins, followed by protein lysates (30 µg/lane) of each group were separated by protein lysates (30 µg/lane) of each group were separated in 3% SDS-PAGE. Proteins were then transferred to PVDF membranes and 5% non-fat milk was used to block membranes at room temperature for 80 min. Rabbit polyclonal PTEN (1:1,400; cat. no. ab31392; Abcam) primary antibodies were incubated with membranes at 4°C for 18 h, followed by incubation with goat anti-rabbit IgG H+L (1:1,000; cat. no. ab6721; Abcam) at room temperature for 2 h. After that, membranes were incubated with RapidStep™ ECL detection reagent (EMD Millipore) at room temperature for 10 min to develop signals. Data was processed using ImageJ v1.46 software (National Institutes of Health).
Cell proliferation assay. SNU-398 cells were counted, and 3x10^4 cells per well were mixed with 1 ml mixture of 10% FBS and 90% RPMI 1640 medium to prepare single-cell suspensions. Cells were cultivated in a 96-well plate (0.1 ml per well) under conditions of 37˚C, 95% humidity and 5% CO_2_. Cell Counting Kit-8 solution (Sigma-Aldrich; Merck KGaA) was added into each well (10 µl per well) at 4 h before the end of cell culture. After cell culture, 10 µl DMSO was added and optical density values were measured at 450 nm wavelength using a microplate reader (Thermo Fisher Scientific, Inc.).

Statistical analysis. Statistical analyses were performed using SPSS version 23 (IBM Corp.). Data were expressed as mean values ± standard deviation of three biological replicates. Associations were analyzed by linear regression. Differences between two types of tissue and among different cell groups were analyzed using paired t-tests and ANOVA (one-way) in combination with the Tukey's test, respectively. Survival analyses were performed by dividing the 64 patients with HCC into high and low MT1JP level groups (n=32) according to the median of MT1JP expression (2.34) in HCC tissues. Kaplan-Meier plotter and log-rank tests were used to plot and compare survival curves. P<0.05 was considered to indicate a statistically significant difference.

Results

MT1JP is downregulated in HCC and predicts poor survival. To illustrate the role of MT1JP in the progression of HCC, the expression of MT1JP and the basic information, such as clinical pathological features of patients with HCC, are displayed in Table I. The expression levels of MT1JP in non-tumor and HCC tissues were measured by qPCR and compared using a paired t-test. Compared with non-tumor tissues, significantly lower expression levels of MT1JP were observed in HCC tissues (P<0.05; Fig. 1A). Compared with patients in the high MT1JP level group, a significantly lower overall 5-year survival rate was observed in the low MT1JP level group (P=0.0078; Fig. 1B). It is worth noting that the expression levels of MT1JP were not significantly affected by HBC and HCV infections as well as clinical stages (data not shown).

Expression of MT1JP is associated with the expression of PTEN and miR-32 in HCC. The expression levels of PTEN and miR-32 were also measured by qPCR and compared using paired t-tests between non-tumor and HCC tissues. Compared with non-tumor tissues, significantly lower expression levels of PTEN (Fig. 2A) and significantly higher expression levels of miR-32 (Fig. 2B) were observed in HCC tissues (both P<0.05). Regression analysis showed that the expression of MT1JP in HCC tissues was positively associated with the expression of PTEN (Fig. 2C) and negatively associated with the expression of miR-32 (Fig. 2D).

MT1JP upregulates PTEN through downregulation of miR-32 in HCC cells. MT1JP and PTEN expression vectors, as well as miR-32 mimic, were transfected into SNU-398 cells and their expression levels were measured by qPCR at 24 h post-transfection. Compared with C and NC, the expression levels of MT1JP, miR-32 and PTEN were significantly increased (all P<0.05; Fig. 3A). Moreover, overexpression of MT1JP decreased the expression levels of miR-32 (P<0.05), whilst overexpression of miR-32 did not affect the expression of MT1JP (Fig. 3B). In addition, overexpression of miR-32 inhibited the mRNA and protein levels of PTEN (P<0.05),
ZHANG et al: MT1JP OVEREXPRESSION ABOLISHES THE SILENCING OF PTEN

which could be reversed by simultaneous upregulation of MT1JP (Fig. 3C).

**MT1JP inhibits HCC cell proliferation through PTEN and miR-32.** The effects of overexpression of MT1JP, miR-32 and PTEN on the proliferation of SNU-398 cells were analyzed using a cell proliferation assay. Compared with NC and C, overexpression of MT1JP and PTEN resulted in significantly inhibited proliferation of HCC cells (P<0.05). miR-32 promoted cell proliferation. Moreover, the suppressive effect of MT1JP on cell proliferation was reversed by miR-32 (P<0.05; Fig. 4).

**Discussion**

The present study investigated the function of MT1JP in HCC. It was found that MT1JP was downregulated in HCC and was associated with the survival of patients with HCC. In HCC, MT1JP may have upregulated PTEN through miR-32 to inhibit the proliferation of HCC cells.

MT1JP is shown to be downregulated in tissues of different types of cancer (23), such as gastric cancer (24), glioma (25) and bladder cancer (26). A recent study has demonstrated the inhibitory effect of MT1JP on the progression of HCC (27).
This study found that MT1JP promotes apoptosis and inhibits cell proliferation and migration by inhibiting the expression of miR-24-3p. However, the study did not thoroughly explore the function of miR-24-3p target genes and the interaction of MT1JP, miR-24-3p and miR-24-3p target genes. Based on this, the present study explored another miRNA (miR-32) regulated by MT1JP and revealed that MT1JP promoted the expression of the miR-32 target gene PTEN. This was investigated by downregulating the expression of miR-32, thereby exerting an antitumor effect, which inhibited the proliferation of HCC cells.

PTEN is a dual phosphatase with both protein and lipid phosphatase activities. Gao et al. (29) revealed that PTEN is concomitantly downregulated in breast cancer tissues and cell lines, and overexpression of PTEN inhibits the progression of breast cancer. Wang et al. (30) reported that PTEN inhibits the development of gastric cancer. The present study observed reduced expression levels of PTEN after the overexpression of miR-32, which further confirmed the targeting of PTEN by miR-32. The miR-32/PTEN axis can be modulated by certain lncRNAs, such as GAS5, to regulate cancer cell malignant behaviors (31). The present research showed that MT1JP can upregulate PTEN by inhibiting the expression of miR-32, thereby inhibiting cell proliferation. Moreover, previous studies have found that the PTEN promoter contains a p53-binding element. Thus, p53-mediated cell death requires coordinated repression of the cellular survival machinery via direct activation of PTEN transcription by p53 (32). Another study has shown that MT1JP enhances p53 translation by binding to the RNA binding protein TIAR, thereby regulating p53-related pathways such as cell cycle, apoptosis and proliferation (23). Therefore, MT1JP may also inhibit tumor growth through P53/PTEN signaling.

There are certain limitations to the current study. First, the effects of MT1JP/miR-32/PTEN on several signaling pathways remain to be elucidated. MT1JP could target multiple miRNAs to regulate its function in HCC, therefore other potential target miRNAs should be investigated. This study lacks in vivo trials, and our conclusions need to be validated in vivo in the future.
In conclusion, MT1JP played a tumor-suppressive role in HCC by upregulating PTEN through downregulation of miR-32 to suppress HCC cell proliferation.

Acknowledgements
Not applicable.

Funding
The study was funded by The 2020 General Program (Major Project) of Wuhan Municipal Health Commission (grant nos. WX20B04) and The General Project of Natural Science Foundation of Hubei Province in 2020 (grant no. 2020CFFB796).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
SZ and JX developed the project, carried out the experiments and clinical studies, collected the data and wrote the manuscript. QC and FZ collected the data, carried out the experiments and clinical studies, analyzed the data and edited the manuscript. HW and HG analyzed the data and carried out the literature research. SZ and JX confirm the authenticity of all raw data. All contributing authors have read and agreed to the final version of the manuscript.

Ethics approval and consent to participate
The Ethics Committee of Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology approved the study (Wuhan, China). Written informed consent was obtained from all individual participants.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Chen Z, He M, Chen J, Li C and Zhang Q: Long non-coding RNA SNHG7 inhibits NLRP3-dependent pyroptosis by targeting the miR-34a/SIRT1 axis in liver cancer. Oncol Lett 20: 893-901, 2020.
2. Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781, 2010.
3. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
4. Xu J and Xu Y: The IncRNA MEG3 downregulation leads to osteoarthritis progression via miR-16/SMAD7 axis. Cell Biosci 7: 69, 2017.
5. Liu J, Tang T, Wang GD and Liu B: IncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARgamma axis in non-alcoholic fatty liver disease. Biosci Rep 39: BSR20181722, 2019.
6. Yang CA, Li JP, Yan JC, Lai IL, Ho YC, Chen YC, Lan JL and Chang JG: IncRNA NTT/PBOV1 axis promotes monocyte differentiation and is elevated in rheumatoid arthritis. Int J Mol Sci 19: 2806, 2018.
7. Harris WS: Long non-coding RNAs and human disease. Biochem Soc Trans 40: 902-906, 2012.
8. Jiang MC, Ni JJ, Cui WY, Wang BY and Zhuo W: Emerging roles of IncRNA in cancer and therapeutic opportunities. Am J Cancer Res 9: 1354-1366, 2019.
9. Wang Z, Huang D, Huang J, Nie K, Li X and Yang X: IncRNA TET2-AS1 exerts oncogenic roles in HCC through regulating miR-320a/SERBP1 axis. Oncol Targets Ther 13: 6539-6551, 2020.
10. Teng F, Zhang JX, Chang QM, Wu XB, Tang WG, Wang JF, Zhang ZP and Hu QZ: IncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/EGF7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 39: 235, 2020.
11. Liu X, Peng D, Cao Y, Zhu Y, Yin J, Zhang G, Peng X and Meng Y: Upregulated IncRNA DLX6-AS1 underpins hepatocellular carcinoma progression via the miR-513c/Cull4A/ANXA10 axis. Cancer Gene Ther 28: 486-501, 2021.
12. Wei F, Yang L, Jiang D, Pan M, Tang G, Huang M and Zhang J: Long noncoding RNA DUXAP8 contributes to the progression of hepatocellular carcinoma via regulating miR-422a/PDK2 axis. Cancer Med 9: 2490-2490, 2020.
13. Komoll RM, Hu Q, Ollerejova O, von Düren L, Yuan Q, Xie Y, Tsay HC, Daon J, Qin R, Manns MP, et al: MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma. J Hepatol 74: 122-134, 2021.
14. Zhang Y, Pan Q and Shao Z: Tumor-Suppressive role of microRNA-202-3p in hepatocellular carcinoma through the KDM3A/HOXA1/MEIS3 pathway. Front Cell Dev Biol 8: 556004, 2021.
15. Zhao L, Han T, Li Y, Sun J, Zhang S, Liu Y, Shan B, Zheng D and Shi J: The IncRNA SNHG5/miR-32 axis regulates gastric cancer cell proliferation and migration by targeting KLF4. FASEB J 31: 893-903, 2017.
16. Zhang Y, Wang J, An W, Chen C, Wang W, Zhu C, Chen F, Chen H, Zheng W and Gong J: MiR-32 inhibits proliferation and metastasis by targeting EZH2 in glioma. Technol Cancer Res Treat 18: 153033819854132, 2019.
17. Liu YJ, Zhou HG, Chen LH, Qu DC, Wang CJ, Xia ZY and Zheng JH: MiR-32-5p regulates proliferation and metastasis of cervical cancer cells by targeting HOX8. Eur Rev Med Pharmacol Sci 23: 87-95, 2019.
18. Carnero A, Blanco-Aparicio C, Renner O, Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Opin Pharmacol 8: 187-198, 2008.
19. Chalhoub N and Baker SJ: PTEN and the PI3K pathway in cancer. Treat 18: 153033819854132, 2019.
20. Yan SY, Chen MM, Li GM, Wang YQ and Fan JG: MiR-32 induces cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting PTEN. Tumour Biol 36: 4747-4755, 2015.
21. Zhang Y, Zhu Z, Huang S, Zhao Q, Huang C, Tang Y, Sun C, Zhang Z, Wang L, Chen H, et al: IncRNA XIST regulates proliferation and migration of hepatocellular carcinoma cells by acting as miR-497-5p molecular sponge and targeting PDCD4. Cancer Cell Int 19: 198, 2019.
22. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
23. Liu L, Yue H, Liu Q, Yuan J, Li J, Wei G, Chen X, Lu Y, Guo M, Luo J and Chen R: IncRNA MT1JP functions as a tumor suppressor by interacting with TIA1 to modulate the p53 pathway. Oncotarget 7: 15787-15800, 2016.
24. Xu Y, Zhang G, Zou C, Zhang H, Gong Z, Wang W, Ma G, Jiang P and Zhang W: IncRNA MT1JP suppresses gastric cancer cell proliferation and migration through MT1JP/miR-214-3p/RUNX3 axis. Cell Physiol Biochem 46: 2445-2450, 2018.
25. Chen J, Lou J, Yang S, Lou J, Liao W, Zhuo R, Qu C and Ding G: MT1JP inhibits glioma progression via negative regulation of miR-24. Oncol Lett 19: 334-342, 2020.
26. Yu H, Wang S, Zhu H and Rao D: IncRNA MT1JP functions as a tumor suppressor via regulating miR-214-3p expression in bladder cancer. J Cell Physiol: Feb 20, 2019 (Epub ahead of print). doi: 10.1002/jcp.28274.
27. Wu JH, Xu K, Liu JH, Du LL, Li XS, Su YM and Liu JC: IncRNA MT1JP inhibits the malignant progression of hepatocellular carcinoma through regulating AKT. Eur Rev Med Pharmacol Sci 24: 6647-6656, 2020.

28. Chen CY, Chen J, He L and Stiles BL: PTEN: Tumor suppressor and metabolic regulator. Front Endocrinol (Lausanne) 9: 338, 2018.

29. Gao X, Qin T, Mao J, Zhang J, Fan S, Lu Y, Sun Z, Zhang Q, Song B and Li L: PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway. J Exp Clin Cancer Res 38: 256, 2019.

30. Wang YN, Xu F, Zhang P, Wang P, Wei YN, Wu C and Cheng SJ: MicroRNA-575 regulates development of gastric cancer by targeting PTEN. Biomed Pharmacother 113: 108716, 2019.

31. Gao ZQ, Wang JF, Chen DH, Ma XS, Wu Y, Tang Z and Dang XW: Long non-coding RNA GAS5 suppresses pancreatic cancer metastasis through modulating miR-32-5p/PTEN axis. Cell Biosci 7: 66, 2017.

32. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S and Mak TW: Regulation of PTEN transcription by p53. Mol Cell 8: 317-325, 2001.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.